| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total operating expense | NaN | 15,839 | 19,166 | NaN |
| Other income, net | NaN | 6,738 | 430 | NaN |
| Loss on disposal of property and equipment | NaN | NaN | NaN | -2 |
| Net loss | -1,174 | -9,101 | -18,736 | -47,964 |
| Depreciation and amortization expense | 21 | 290 | 229 | 537 |
| Impairment of long-lived assets | NaN | 1,112 | NaN | NaN |
| Non-cash lease expense | 185 | 330 | 326 | 508 |
| Stock-based compensation expense | 423 | 1,661 | 1,424 | 3,628 |
| Change in fair value of warrant liability | -9,640 | -6,429 | -2,099 | NaN |
| Offering costs recognized in other expense, net | NaN | 0 | 2,046 | NaN |
| Prepaid expenses and other current assets | 195 | 2,288 | 209 | -718 |
| Other non-current assets | -36 | -37 | -42 | -628 |
| Accounts payable | -3,781 | -2,946 | 1,132 | 4,007 |
| Accrued expenses and other current liabilities | 55 | -4,065 | -700 | 391 |
| Operating lease liability | -478 | -468 | -452 | -750 |
| Net cash used in operating activities | -14,548 | -21,867 | -16,999 | -38,295 |
| Purchases of property and equipment | NaN | 0 | 0 | 7 |
| Proceeds from sales of property and equipment | NaN | 0 | 0 | 12 |
| Proceeds from exercise of common stock options | NaN | NaN | NaN | 0 |
| Net cash provided by (used in) investing activities | NaN | 0 | 0 | 5 |
| Proceeds from issuance of common stock through atm offering, net | NaN | 0 | 514 | 5,940 |
| Proceeds from issuance of common stock and warrants through underwritten offering, net | NaN | -360 | 27,874 | NaN |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | NaN | 20 | 0 | 223 |
| Net cash provided by financing activities | NaN | -340 | 28,388 | 6,163 |
| Net decrease in cash, cash equivalents and restricted cash | -14,548 | -22,207 | 11,389 | -32,127 |
| Cash, cash equivalents and restricted cash at beginning of the period | 29,109 | 51,316 | 72,054 | NaN |
| Cash, cash equivalents and restricted cash at end of the period | 14,561 | 29,109 | 51,316 | NaN |
Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc. (JSPR)